Program overview
Context
Indication: Rectal Neoplasms
Mechanism: Unknown
Modality: Unknown
Sponsor: National Cancer Center, Korea
Watchlist Signal
Cetuximab, Irinotecan, Capecitabine
Cetuximab, Irinotecan, Capecitabine is flagged as watchlist signal because public records show timeline staleness. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 3/5
Timeline: 2/5
Recruitment burden: 0/5
Results availability: 0/5
Program risk: 2/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT00506844
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT00506844 | Unknown Status Signal (UNKNOWN) | stale_update_signal | completion_date_past_signal | Low Signal | None |